back to overview


Final Closing of MTIP Fund 1

April 01, 2017 + Jessica Di Palo
5 Min read

Basel, April 2017 – MTIP MedTech Innovation Partners AG has closed its first fund significantly above expectation at CHF 60 million.

MTIP first closing Christoph Kausch

After its launch a year ago, MTIP’s first fund closed at a total of just under CHF 60 million. Due to strong investor demand this is considerably higher than the CHF 40 million targeted at the outset. “A first fund of this magnitude is exceptional in the industry and a great success for our investors and us,” explains Dr. Christoph Kausch, CEO of MTIP. The capital comes from institutional investors such as pension funds and family offices, hospitals, foundations and qualified private individuals. MTIP will use this fund to invest in a portfolio of around 10 startups in the medical technology sector. The aim is to support these businesses and to facilitate their further development into successful companies. Having invested in two startups (Coramaze and Reactive Robotics) already, additional investments are expected later this year as MTIP’s project pipeline is looking promising with additional attractive opportunities. “MTIP’s involvement in the innovation landscape, from university research to practical use in hospitals and an understanding of the relevant MedTech players’ portfolio strategies are important success factors in our business model”, emphasises board president Dr. Felix Grisard. In the selection process of companies MTIP places a clear focus on health economic benefits and patient-relevant innovations. MTIP builds sustainable investments that facilitate improved health care at home and abroad and combine economic success with added value for the community.

Share the Article


SFDR Art. 8 or Art. 9? What’s the difference?

SFDR: getting the terminology right


MTIP participates in Oviva’s new $80m Series C funding

Oviva raises $80 million financing round


MTIP invests in Intelligencia to reduce the risk of clinical research through artificial intelligence

MTIP's new investment in Intelligencia


Private Equity 101: Part one – Glossary

Are you new to the healthtech space?


Leading brands revolutionize care journeys with Lumeon

How Lumeon orchestrates care journey


Trialbee – our hero in patient matching and recruiting for clinical trials

Trialbee - patient matching and recruiting

news blog

Digital healthcare: patient-first?

Digital Healthcare Report 2021 in collaboration with Dealroom and INKEF Capital

SFDR – How does MTIP approach the EU’s Sustainable Disclosure Regulation?

New SFDR obligations


MTIP Announces Strong First Closing of Fund II to drive Healthtech Innovation

First Closing of Fund II


How to pitch to a healthtech Investor

Blog Pitching


MTIP invests in Koa Health to make mental health treatment more accessible

New investment in Koa Health


MTIP scored fantastic grades in the UNPRI assessment report of 2020

UNPRI Report grades 2020


4 Health VCs Share Their Business Priorities and What is Next

Interview Techtour


MTIP invests in Trialbee

New investment in Trialbee


TytoCare closes $50 million round as the demand for telehealth accelerates

TytoCare closes new round


The digital healthtech sector is expanding – and so are we!

Two new empolyees start in April


MTIP has sucessfully exited Blueprint Genetics

Blueprint exit January 2020


New MTIP investment in Oviva

New investment in Oviva


Whitepaper: A positive prognosis for the future of healthtech

Our first Whitepaper


Elite Summit 2019 – Interview with our Managing Partner Christoph Kausch

Elite Summit 2019


MTIP Healthcare Clinic 2019

Healthcare clinic 2019

New MTIP investment in Cynerio

New investment in Cynerio


MTIP invests in Lumeon Ltd.

New investment in Lumeon

Magenverkleinerung mit der Handnähmaschine

Nitinotes news paper article


New MTIP investment in Quanta Dialysis Technologies

New investment in Quanta